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9.8 days) and PVT (7.7 ± 8.4days), compared with AMI patients
without ventricular arrhythmia (5.5 ± 6.1 days). Average hospi-
talization costs were signiﬁcantly higher (p < 0.001) in AMI
patients with sustained VT/VF ($26,524 ± 29,869) and PVT
($23,447 ± 27,704) than those for AMI patients without ven-
tricular arrhythmia ($14,449 ± 16,638). CONCLUSIONS: Ven-
tricular arrhythmia in AMI patients was associated with higher
mortality and increased resource utilization. Prevention of ven-
tricular arrhythmia in AMI patients would potentially yield ben-
eﬁts of increased survival and reduced costs.
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OBJECTIVES: The objective of this study was to examine 
prescribing patterns of lipid lowering agents among Medic-
aid/Medicare dual eligible patients by ethnicity. METHODS:
Data came from the Thomson Medstat Marketscan® Medicare
and Medicaid claims databases. Beneﬁciaries who were pre-
scribed these agents during 2003 and enrolled for the full year
in both databases were in the study sample. Logistic regression
models estimated the probability of a switch, augmentation, or
titration up, by ethnicity. Switching was a change in the agent,
augmentation was at least 30 days of overlapping therapy, and
titration upwards was an increase in dosage for two consecutive
prescriptions. RESULTS: There were 239,530 patients included
in the study. Fewer African Americans (9%) switched lipid low-
ering agents than Asians, Hispanics, Caucasians or other eth-
nicities (14%, 13%, 12%, and 13%, respectively) did. Fewer
African Americans (3%) augmented with another agent than
Asians, Hispanics, Caucasians or others (6%, 5%, 6% and 5%).
Logistic regressions showed that African Americans were signif-
icantly less likely to switch (OR 0.68; 95% CI 0.60–0.78),
augment (OR 0.53; 95% CI 0.43–0.66), or titrate up (OR 0.75;
95% CI 0.67–0.84) than Caucasians, controlling for age, gender,
state of residence, days on therapy, number of outpatient visits,
and the Chronic Disease Score. CONCLUSIONS: Results were
consistent with the literature which shows lipid lowering agent
prescribing for African Americans tended to be less aggressive,
as evidenced by fewer switches, less augmentation and less
upward titration. This may reﬂect treatment differentials such as
clinicians being less likely to increase doses of lipid lowering
agents to help these patients reach goal. It may also reﬂect the
effectiveness of these agents in lowering lipid levels and keeping
patients at consistently low levels. These treatment issues merit
further observation as dual eligibles move into Medicare part D
plans with differing coverage and formulary restrictions.
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OBJECTIVES: Examine use and cost of inpatient, emergency
department (ED), and observation unit (OU) services during one
year by patients treated for congestive heart failure (CHF).
METHODS: Using 2001–2002 Massachusetts hospital, ED and
OU data, a cohort of adult patients (age: 18+ years) with CHF
(ICD-9 principal diagnosis code: 428.0–428.9) was identiﬁed. A
patient CHF encounter proﬁle was established starting with the
ﬁrst stay/visit (index encounter) at any hospital, ED or OU in
2001 and included all subsequent inpatient, ED or OU care for
CHF within 12 months. Charges (accommodations, ancillary
services) adjusted by a 0.55 cost-to-charge ratio, medical inﬂa-
tion and geographic factors are reported as 2005 US$ costs.
RESULTS: The patient cohort (n: 18,550; females: 56%; mean
age: 61 years, range: 18–104) used a combined total of 28,673
CHF-related hospitalizations, ED and OU stays during one year
(mean encounters: 1.5, range: 1–29). Of all encounters, 84%
were inpatient, 12% ED and 4% OU. Only inpatient care was
used by 79% of the cohort (mean stays: 1.4, range: 1–16); 8%
ED only (mean visits: 1.1, range: 1–19); 3% OU only (mean
stays: 1.1, range: 1–3); 9% used multiple care settings (mean
encounters: 3, range: 2–12); and 1% used all (mean encounters:
5.2, range: 3–29). Patients with inpatient plus ED or OU care
had a signiﬁcantly (p < 0.01) greater readmission rate (44%) for
CHF than those utilizing only inpatient care (26%). On average,
hospital length of stay was 5.4 days, cost: $7736; ED visit: 4.7
hours, cost: $740; OU stay: 29 hours, cost: $2468, per encounter.
Cumulative cost for hospital, ED and OU care for one year was
roughly $190 million. CONCLUSIONS: Inpatient care was the
dominant non-routine setting for acute management of CHF.
Those utilizing multiple acute care locations are more likely to
have multiple hospitalizations within one year.
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OBJECTIVES: Prior authorization (PA), the requirement of
physicians to obtain pre-approval as a prerequisite for coverage
may decrease drug utilization via a “sentinel effect”, a decrease
in utilization caused by external review of prescribing. The
purpose of this study was to assess the affect a PA restriction had
on the utilization patterns of cefuroxime tablets in a Managed
Care Organization (MCO) in Israel. METHODS: Prescribing
patterns were evaluated from electronic patient records. A ret-
rospective drug-utilization analysis was conducted. All prescrip-
tions for solid state antibiotics for patients diagnosed with an
infectious disease during three parallel, three month segments:
before, during, and after a PA restriction for cefuroxime was
enforced were included. Frequency and proportion of antibiotic
prescriptions for cefuroxime, distribution of infectious diseases
treated with cefuroxime, and the request rejection rate when PA
was required were calculated. RESULTS: Prescription of
cefuroxime declined from 5538 (8.0% of eligible antibiotic pre-
scriptions, 95% CI = 7.8, 8.2) in the initial period to 1036
(1.2%, 95% CI = 1.1, 1.3) during the PA period, rising to 3961
(4.3%, 95% CI = 4.2, 4.4) in the post-PA period. Changes in the
distribution of diseases treated with cefuroxime during the PA
stage tended to regress after revocation to those observed in 
the pre-PA period. The rejection rate was 8.5% (95% CI =
6.9–10.1). CONCLUSIONS: Although a PA requirement for
cefuroxime markedly reduces utilization probably due to a “sen-
tinel effect”, it will not lead to residual effects on prescribing
behavior upon its revocation, indicating the need for a multi-
pronged approach in the realm of policy, regulation and man-
agement regarding prescribing behavior. While many articles
have alluded to the need to create a “culture of quality”, we
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suggest a multi-pronged approach including focus groups and
surveys of physicians, implementation of clinical guidelines, and
ongoing feedback in an Israeli MCO.
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OBJECTIVES: Serious candida infections have been treated with
a variety of patterns of antifungal drugs. This study focused on
the outcomes of hospitalized patients treated with antifungal
drugs and examined drug switching approaches in actual prac-
tice. METHODS: A retrospective study was conducted among a
population of 9746 serious candida infection patients treated
with antifungal drugs during the time period of February 2003
to June 2005. Data was collected from 441 hospitals out of the
Solucient® ACTrackertm database. Patients were categorized
into an adherence group with patients staying in aggressive drugs
(IV forms of amphotericin B, amphotericin B lipids, cancidas and
vfend) and a switching group with patients who switched from
aggressive drugs to non-aggressive and less expensive drugs (oral
forms only of amphotericin B, sporanox, diﬂucan & vfend).
Mortality and length of stay (LOS) of the two groups were com-
pared by Chi square and T test. Further analysis was followed
by using Logistics regression and ANCOVA analysis with con-
trolled inﬂuencing factors such as co-morbidities. RESULTS: The
drug switching patients group was found to have signiﬁcantly
higher mortality rate (0.246 vs 0.160, Chi = 29.68, p < 0.001)
and longer LOS (36.45 vs 27.73, t = 7.67, p < 0.001) as com-
pared to adherence group. The higher mortality in switching
group was supported by Logistic regression results with the 
following confounding factors controlled: age (OR 1.013,
CI:1.009–1.017), septicemia (OR 1.231, CI:1.055–1.451),
kidney disease(OR 1.288, CI:1.091–1.52), ER(OR 1.362,
CI:1.083–1.712) and other candida (OR 1.440,
CI:1.039–1.996). The extended LOS also was found by using
ANCOVA with confounding factors adjusted including mycoses,
ER admission, Medicare payment. CONCLUSIONS: The study
demonstrated that switching aggressively treated patients to
cheaper and less aggressive drugs caused higher mortality and
extended hospital stay. More extensive clinical and economic
outcome studies are needed to understand antifungal drug treat-
ment in candida infection patients.
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OBJECTIVES: Describe US treatment experience trends, shifts
in employment status, insurance, and CD4 counts of HIV/AIDS
patients since the introduction of highly active antiretroviral
therapy (HAART) in 1996. METHODS: HIV-infected patients
(n = 3203) treated at US clinics from 1996–2004 as part of the
HIV Insight database* were studied. Longitudinal patient
records were analyzed to track the changing distribution of anti-
retroviral treatment experience by year. Patients having at least
six months of follow-up and enrollment in the reporting year
were classiﬁed into four treatment experience groups: Nucleo-
side Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside
Reverse Transcriptase Inhibitors (NNRTI), Protease Inhibitor
(PI), and 3-class experience. Demographic shifts were observed
for: employment and disability status, and primary insurance
type. CD4 counts were examined by treatment experience level.
RESULTS: Of the 3203 patients with active enrollment, 2552
were treated. Average follow-up was 3.84 and 4.33 years, respec-
tively. The percentage of patients with treatment experience
increased substantially in all 4 groups (1996–2004): NRTI (48%,
98%), NNRTI (4%, 67%), PI (25%, 63%), 3-class (<1%, 36%).
The percentage of patients working (part/full-time) increased
from 49% to 62% from 1996 to 2004. The percentage of dis-
abled patients decreased from 22% to 15%. Primary insurance
coverage for treated patients was distributed as follows
(1996–2004): Private insurance (50%, 60%), Medicare (10%,
7.4%), Medicaid (30%, 20%), AIDS Drug Assistance Programs
(ADAP) (2.7%, 5.0%), and Other (7.5%, 8.4%). Lower CD4
counts correspond with more treatment experienced patients.
CONCLUSIONS: While increased use of HAART therapy cor-
responds with better employment status and increased private
insurance, patients who have more treatment experience have
lower CD4 counts, signaling a need for more effective treatment
options. *Includes data from the CDC’s HIV Outpatient Study,
and other US HIV care-sites funded by Cerner Corporation. The
ﬁndings and conclusions are the authors’ and don’t represent the
views of the CDC/US DHHS.
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OBJECTIVES: There is a paucity of published research address-
ing how the Infectious Disease Society of America guidelines for
empiric treatment of CAP are implemented in clinical practice.
The current study was designed to describe antibiotic treatment
patterns among Medicare managed care patients with CAP
treated in ambulatory settings in light of these guidelines.
METHODS: This study used claims data from a Medicare
managed care organization located throughout geographically
diverse regions of the US. Patients with pneumonia treated with
any antibiotic in ambulatory settings during 2004 were retro-
spectively identiﬁed via ICD-9CM codes (481–486). Recent
antibiotic use was identiﬁed through NDC and J codes, and
deﬁned as receipt of any antibiotics within 90 days prior to the
date of diagnosis. Individuals were divided into four groups as
per guidelines: G1) previously healthy without recent antibiotics;
G2) previously healthy with recent antibiotics; G3) with comor-
bidities (including COPD, diabetes, renal or congestive heart
failure, or malignancy) and without recent antibiotics; AND G4)
with comorbidities and recent antibiotics. RESULTS: Of 2186
patients identiﬁed, 59% had comorbidities. The mean age was
76.6 years and 61% were female. Among G1 patients (n = 661),
guideline compliance was 41% (recommended treatment: a
macrolide or doxycycline). For G2 patients (n = 230), guideline
compliance was 40% (recommended treatment: a respiratory
quinolone alone, or an advanced macrolide plus amoxicillin or
augmentin). A high compliance rate was observed among G3
patients with comorbidities and without recent antibiotics (n =
861) (72%; recommended treatment: an advanced macrolide or
respiratory quinolone). For G4 patients with comorbidities and
recent antibiotics (n = 434), guideline compliance was 39% (rec-
ommended treatment: a respiratory quinolone alone or advanced
macrolide plus beta-lactam). CONCLUSION: These data,
reﬂecting a period shortly after the CAP guidelines were pub-
